In a breakthrough, researchers have for the first time in 20 years developed a new asthma pill which may have the power to significantly reduce the severity of the condition. Fevipiprant significantly decreases the symptoms of asthma, improves lung function, reduces inflammation and repairs the lining of airways, researchers said. “This new drug could be a game changer for future treatment of asthma,” said Christopher Brightling from University of Leicester in the UK.
The first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, the study found. The drug is currently being evaluated in late stage clinical trials for efficacy in patients with severe asthma. A total of 61 people took part in the research. One group was given 225 milligrammes of the drug twice a day for 12 weeks and the other participants were assigned to a placebo group. Fevipiprant and the placebo were added to the medications the participants were already taking. The study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.

No Comments

Leave a Comment